ストックスクリーナーアプリを入手
64.17
730.14%
56.44
プレマーケット:
45.03
-19.14
-29.83%
前日終値:
$7.73
開ける：
$21.07
24時間の取引高:
47.58M
Relative Volume:
65.34
時価総額：
$30.20M
収益：
-
当期純損益:
$-24.77M
株価収益率:
-87.90
EPS:
-0.73
ネットキャッシュフロー:
$-17.36M
1週間 パフォーマンス:
+787.38%
1か月 パフォーマンス:
+745.45%
6か月 パフォーマンス:
+777.84%
1年 パフォーマンス:
+562.37%
1日の値動き範囲:
$20.20
$76.00
1週間の範囲:
$7.01
$76.00
52週間の値動き範囲:
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
INKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
64.17 | 30.20M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mink Therapeutics Inc (INKT) 最新ニュース
MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 815% last week - Yahoo Finance
Why Did MiNK Therapeutics Plunge 31.92% After William Blair Downgrade? - AInvest
MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 787% last week - simplywall.st
MiNK Therapeutics: Leading the Allogeneic Cell Therapy Revolution with AgenT-797's Durable Solid Tumor Responses - AInvest
MiNK Therapeutics: AgenT-797 Solidifies Itself As iNKT Cell Therapy With Latest CR Data - Seeking Alpha
Best Medical Stocks To Keep An Eye On – July 11th - Defense World
MiNK Therapeutics' iNKT Cell Therapy: A Breakthrough in Solid Tumors and a Catalyst for Stock Upside - AInvest
MiNK Therapeutics Announces Publication of Complete - GlobeNewswire
Mink Therapeutics shares fall 19.28% in after-hours following publication of case study in Nature's Oncogene. - AInvest
Volume Stonkers | MiNK Therapeutics skyrocketed 730.14%, Significant Advancements in Cancer Treatment Research - AInvest
INKT Stock Quote Price and Forecast - CNN
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge - Benzinga
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? - Benzinga
MiNK Therapeutics soars over 500% after cancer therapy shows complete remission - TradingView
MiNK Therapeutics Says Testicular Cancer Patient Achieves Remission After INKT Cell Therapy - MarketScreener
MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy - Stocktwits
MiNK Therapeutics Soars on Cancer Breakthrough: What’s Driving the INKT Surge? - RagingBull
MiNK Therapeutics stock soars after cancer remission breakthrough - Investing.com
MiNK reports complete remission in refractory testicular cancer case By Investing.com - Investing.com South Africa
MiNK Therapeutics Publishes Landmark Case of Complete Remission in Metastatic Testicular Cancer Following Treatment with AgenT-797 - Nasdaq
Complete Remission Achieved in Treatment-Resistant Testicular Cancer with iNKT Cell Therapy | INKT Stock News - Stock Titan
MiNK Therapeutics (NASDAQ:INKT) Trading 0.6% Higher – Should You Buy? - Defense World
Where are the Opportunities in (INKT) - news.stocktradersdaily.com
Kalkine: MiNK Therapeutics Sees Gains Amid Positive Earnings Per Share Momentum - Kalkine Media
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting - Eagle-Tribune
MiNK Therapeutics Annual Meeting: How Shareholders Can Join Virtually on June 18 - Stock Titan
MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 0.1% – Here’s Why - Defense World
MiNK Therapeutics receives NIH grant for GvHD therapy - Investing.com India
MiNK Therapeutics, Inc. Awards Prestigious Niaid Grant to Advance Allo-Inkt Cell Therapy for Prevention of Gvhd in Stem Cell Transplant Patients - MarketScreener
INKT Secures Grant for GvHD Cell Therapy Development | INKT Stoc - GuruFocus
MiNK Therapeutics Receives NIAID Grant to Advance Allo-iNKT Cell Therapy for Graft-Versus-Host Disease Treatment - Nasdaq
MiNK Therapeutics Awarded Prestigious NIAID Grant to - GlobeNewswire
NIH Backs Revolutionary Cell Therapy: MiNK's Solution Could Prevent Deadly Transplant Complications - Stock Titan
(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Amer Sports: The New ONON and DECK of Consumer Discretionary? - The Globe and Mail
MiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programs - MSN
HC Wainwright Cuts Earnings Estimates for MiNK Therapeutics - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Mink Therapeutics’ Earnings Call Highlights Progress and Optimism - TipRanks
Transcript : MiNK Therapeutics, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
MiNK Therapeutics (INKT) Advances in Immune Response Innovation - GuruFocus
MiNK Therapeutics (INKT) Advances in Immune Response Innovation | INKT Stock News - GuruFocus
MiNK Therapeutics Reports Clinical Advancements and Financial Update for Q1 2025, with Focus on iNKT Cell Therapies - Nasdaq
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress - GlobeNewswire
MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World
Refractory Multiple Myeloma Pipeline Appears Robust With 75+ - openPR.com
How to Take Advantage of moves in (INKT) - news.stocktradersdaily.com
MiNK Therapeutics to Announce Q1 2025 Financial Results and Host Conference Call on May 15th - Nasdaq
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewswire
Mink Therapeutics Inc (INKT) 財務データ
収益
当期純利益
現金流量
EPS
2.10%
1.57%
大文字化:
|
ボリューム (24 時間):